tradingkey.logo

Pacira Biosciences Inc

PCRX

22.180USD

+0.110+0.50%
Horário de mercado ETCotações atrasadas em 15 min
1.03BValor de mercado
PerdaP/L TTM

Pacira Biosciences Inc

22.180

+0.110+0.50%
Mais detalhes de Pacira Biosciences Inc Empresa
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
Informações da empresa
Código da empresaPCRX
Nome da EmpresaPacira Biosciences Inc
Data de listagemFeb 03, 2011
CEOMr. Frank D. Lee
Número de funcionários790
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 03
Endereço2000 Sierra Point Parkway
CidadeBRISBANE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94005
Telefone16502428052
Sitehttps://www.pacira.com/
Código da empresaPCRX
Data de listagemFeb 03, 2011
CEOMr. Frank D. Lee
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mark A. Kronenfeld, M.D.
Dr. Mark A. Kronenfeld, M.D.
Independent Director
Independent Director
34.90K
+40.15%
Dr. Jonathan Slonin, M.D.
Dr. Jonathan Slonin, M.D.
Chief Medical Officer
Chief Medical Officer
34.69K
-12.78%
Mr. Daryl Gaugler
Mr. Daryl Gaugler
Executive Vice President - Commercial Operations
Executive Vice President - Commercial Operations
32.29K
-51.29%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Chairman of the Board
Independent Chairman of the Board
23.71K
+35.11%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
11.39K
+117.84%
Ms. Lauren Riker
Ms. Lauren Riker
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
5.98K
-59.94%
Mr. Michael J. Yang
Mr. Michael J. Yang
Independent Director
Independent Director
--
--
Mr. Shawn M. Cross
Mr. Shawn M. Cross
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Marcelo Bigal, M.D., Ph.D.
Dr. Marcelo Bigal, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Susan Mesco
Ms. Susan Mesco
Investor Relations
Investor Relations
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mark A. Kronenfeld, M.D.
Dr. Mark A. Kronenfeld, M.D.
Independent Director
Independent Director
34.90K
+40.15%
Dr. Jonathan Slonin, M.D.
Dr. Jonathan Slonin, M.D.
Chief Medical Officer
Chief Medical Officer
34.69K
-12.78%
Mr. Daryl Gaugler
Mr. Daryl Gaugler
Executive Vice President - Commercial Operations
Executive Vice President - Commercial Operations
32.29K
-51.29%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Chairman of the Board
Independent Chairman of the Board
23.71K
+35.11%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
11.39K
+117.84%
Ms. Lauren Riker
Ms. Lauren Riker
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
5.98K
-59.94%
Detalhamento da receita
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
EXPAREL
136.53M
0.00%
ZILRETTA
23.34M
0.00%
iovera
5.12M
0.00%
Bupivacaine liposome injectable suspension
2.60M
0.00%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
EXPAREL
136.53M
0.00%
ZILRETTA
23.34M
0.00%
iovera
5.12M
0.00%
Bupivacaine liposome injectable suspension
2.60M
0.00%
Distribuição de ações
Atualizado em: dom, 13 de jul
Atualizado em: dom, 13 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
14.61%
The Vanguard Group, Inc.
11.21%
D. E. Shaw & Co., L.P.
4.89%
Renaissance Technologies LLC
4.84%
Dimensional Fund Advisors, L.P.
4.43%
Other
60.03%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
14.61%
The Vanguard Group, Inc.
11.21%
D. E. Shaw & Co., L.P.
4.89%
Renaissance Technologies LLC
4.84%
Dimensional Fund Advisors, L.P.
4.43%
Other
60.03%
Tipos de investidores
Investidores
Proporção
Investment Advisor
49.40%
Hedge Fund
27.65%
Investment Advisor/Hedge Fund
25.71%
Research Firm
5.57%
Pension Fund
1.69%
Individual Investor
1.48%
Bank and Trust
1.05%
Sovereign Wealth Fund
0.32%
Holding Company
0.31%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
611
52.44M
113.25%
-16.62M
2025Q1
638
53.73M
116.03%
-16.46M
2024Q4
638
52.13M
112.66%
-21.91M
2024Q3
638
53.62M
116.22%
-11.06M
2024Q2
624
54.29M
116.65%
-6.10M
2024Q1
627
51.47M
110.71%
-7.99M
2023Q4
621
50.55M
108.88%
-6.71M
2023Q3
612
49.73M
107.18%
-6.05M
2023Q2
605
49.27M
107.14%
-5.45M
2023Q1
601
48.56M
105.72%
-5.54M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
6.77M
14.61%
-179.41K
-2.58%
Mar 31, 2025
The Vanguard Group, Inc.
5.19M
11.21%
-25.27K
-0.48%
Mar 31, 2025
D. E. Shaw & Co., L.P.
2.26M
4.89%
+6.43K
+0.29%
Mar 31, 2025
Renaissance Technologies LLC
2.24M
4.84%
+248.00K
+12.45%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.05M
4.43%
+217.22K
+11.86%
Mar 31, 2025
State Street Global Advisors (US)
1.98M
4.27%
+13.89K
+0.71%
Mar 31, 2025
DOMA Perpetual Capital Management, LLC
1.80M
3.9%
+56.22K
+3.22%
Mar 31, 2025
Balyasny Asset Management LP
1.57M
3.38%
+1.13M
+260.53%
Mar 31, 2025
Citadel Advisors LLC
1.33M
2.87%
+1.28M
+2700.84%
Mar 31, 2025
Alyeska Investment Group, L.P.
1.31M
2.83%
+1.31M
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Pacer US Small Cap Cash Cows Growth Leaders ETF
2.97%
SPDR S&P Pharmaceuticals ETF
2.6%
Invesco Pharmaceuticals ETF
2.5%
Simplify Health Care ETF
2.21%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.85%
Invesco S&P SmallCap Health Care ETF
0.79%
VictoryShares Small Cap Free Cash Flow ETF
0.76%
iShares U.S. Pharmaceuticals ETF
0.56%
Royce Quant Small-Cap Quality Value ETF
0.53%
Distillate Small/Mid Cash Flow ETF
0.45%
Ver Mais
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporção2.97%
SPDR S&P Pharmaceuticals ETF
Proporção2.6%
Invesco Pharmaceuticals ETF
Proporção2.5%
Simplify Health Care ETF
Proporção2.21%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.85%
Invesco S&P SmallCap Health Care ETF
Proporção0.79%
VictoryShares Small Cap Free Cash Flow ETF
Proporção0.76%
iShares U.S. Pharmaceuticals ETF
Proporção0.56%
Royce Quant Small-Cap Quality Value ETF
Proporção0.53%
Distillate Small/Mid Cash Flow ETF
Proporção0.45%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI